Fertility Test Market Size, Share, Opportunities, And Trends By Product (Ovulation Product Kits, Fertility Monitors, Men's Fertility Testing Kits, Others), By Application (Female Fertility Testing, Male Fertility Testing), By Mode Of Purchase (Prescription Based, Non-Prescription Based), By End-User (Homecare Setting, Hospitals And Fertility Clinics), And By Geography - Forecasts From 2024 To 2029

The fertility test market is expected to grow at a CAGR of 5.54% over the forecast period, reaching a market size of US$775.732 million in 2029 from US$531.831 million in 2022.

Fertility Testing is a process through which males and females are made aware of their reproductive health, which helps them to detect ovulation and to diagnose infertility. This procedure aids in planning pregnancy and helps doctors diagnose the cause of infertility as well. The growing age of the population and the declining fertility rate are expected to be the primary market drivers. This is because fertility testing can be considered a safe option to detect pregnancy or ovulation and infertility for people trying to get pregnant at high ages.

Besides that, the growing prevalence of PCOS and PCOD among females is considered another major factor that is driving up the fertility test market. Today technology is thriving, and easy-to-use fertility monitors and kits are in wide demand in the fertility test market, thus constituting a vital growth factor for the fertility test market. In the past few years, fertility tourism has surged significantly, holding an opportunity for the fertility test market to grow at a notable rate in the coming years.

Another considerable contribution to this market is the growing self-health awareness among women. Government and authorities at times set up campaigns and awareness programs to provide the required self-health literacy to women in both developed and developing nations. With the increased awareness, the demand for fertility testing is projected to increase in the coming years.

Although the market includes several growth opportunities, one of the major restraints is that these tests, at times, can generate false results that can hamper the market growth in the future.

Market Drivers:

• Declining birth rate and growing age of first-time pregnancies are expected to surge the market growth.

The decline in fertility rates in major countries around the globe has become a serious concern. The birth rate of 2.1 is considered an ideal rate for a country to naturally replace its population. As reported by the World Economic Forum, the United States’ most recent survey showed that its birth rate has been on a continuous decline for the past six years, and its current rate is at 1.6. The report also showed that the birth rate in China and Japan stands at 1.3 while that in Russia, Brazil, and Bangladesh stands at 1.6, 1.8, and 1.7, respectively. 

One of the major reasons behind this is the growing age of the population which has simultaneously contributed to the increasing age of first-time pregnancies. According to the World Bank, the old-age dependency ratio has increased significantly over the past few decades, and in 2020 it stood at 14.296%. This is expected to be a significant market driver as fertility tests can be considered a safe option to detect the early signs of ovulation and infertility among the high-age population.

• Rising PCOS among females is anticipated to fertility test market growth.

PCOS is one of the major rising causes of infertility among females. PCOS, or Polycystic Ovary Syndrome, is a hormonal disorder that causes enlarged ovaries and small cysts on the outer edges due to which the ovaries fail to release the eggs, which hampers the menstrual cycle and thereby increases the chances of infertility among women.

According to the Centers for Disease Control and Prevention, PCOS affects around 6%-12% (around 5 million) of American women. Since fertility tests can contribute as a primary source of information regarding ovulation and infertility, the prevalence of PCOS is directly related to the high demand for fertility tests in the coming years.

• Fertility tourism is predicted to increase the demand for fertility tests.

Fertility Tourism, or cross-border reproductive care tourism, is traveling from one country to another to overcome fertility issues and get fertility treatment. This practice has become popular in the past few decades owing to factors like strict regulations in domestic countries, better treatment facilities in foreign countries, etc. To work on infertility issues and conceiving problems, fertility tourism involves a high-scale application of fertility tests, which can positively impact its market in the forecasted period.

Market Restraints:

• False results of fertility tests could hinder the fertility test market.

Although the Fertility tests help to get the required information about fertility and ovulation, at times, these tests can detect false results as well. This problem generally arises in the home urine test kits. There can be several causes, like user error, chemical pregnancy, fertility medications, and recent pregnancies, that may leave behind hCG in the bodies. These factors can contribute to the high probability of false result generation, which can hamper market growth.

Key Developments:

• November 2023- Pollin Fertility and The Modern Miracle Foundation launched the Pollin x Modern Miracle IVF Grant Fund in Ontario, offering over $225,000 in inpatient grants to offset fertility treatment costs. The clinic opened in Toronto, aims to overcome affordability, accessibility, and emotional impact barriers for patients. It provideded transparent pricing structures and financing plans and is designed for both in-person and virtual care. The grant is available to Pollin patients with an annual household income of less than $150,000, and applications open on January 8, 2024.
• October 2023- Inception Fertility, North America's largest fertility provider, sponsored the 2023 American Society for Reproductive Medicine's Scientific Congress in New Orleans. The event, from October 14-18, featured multidisciplinary professionals discussing the latest scientific breakthroughs in reproductive endocrinology and infertility. Inception also served as a Champion sponsor for the 2023 President's Gala, combining networking and philanthropy. The company's ecosystem of brands showcased their scientific research and service line offerings, including Prelude Network®, Family Building for Medical Residents, MyEggBank®, and BUNDL Fertility™, which shared developments to improve patient accessibility.
• July 2023- Quest Diagnostics and Proov partnered to introduce the Proov Confirm PdG test, the first FDA-cleared home test kit to confirm successful ovulation. The test measures PdG levels in urine over four key days, known as the "implantation window," to assess ovulation success. The Proov Confirm home collection kit, available for $29 on questhealth.com, can be downloaded for free to receive reminders, interpret results, and personalize an action plan. The test is suitable for women who have failed to conceive, those with prior fertility issues, PCOS, or endometriosis, and those 35 years or older or taking fertility medications.

Segmentation:

• By Product
  • Ovulation Product Kits
  • Fertility Monitors
  • Men's Fertility Testing Kits
  • Others
• By Application
  • Female Fertility Testing
  • Male Fertility Testing
• By Mode of Purchase
  • Prescription based
  • Non-prescription based
• By End-User
  • Homecare setting
  • Hospitals and Fertility Clinics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Others
  • Middle East and Africa
    • UAE
    • South Africa
    • Israel
    • Saudi Arabia
    • Others
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Taiwan
    • South Korea
    • Others